- Featured
on SmallCapVoice.com interview, Warren Wang outlines plans for CIIX subsidiary,
CBD Biotech Inc.
- CBD
Biotech one of few players in China’s fast-growing CBD market
- Company
to focus on hemp/CBD-infused cosmetic products
ChineseInvestors.com
Inc. (OTCQB: CIIX) provides prominent financial information for
Chinese-speaking investors in both China as well as the United States. The
company is also a leading hemp retailer looking to capitalize on the growing
market for hemp/CBD products in China.
During a recent SmallCapVoice.com interview, CIIX CEO Warren
Wang provided updates about CIIX as well as its subsidiary, CBD Biotech (http://ibn.fm/1azD1). In the
interview, Wang explains the enormous market opportunity in China for
CBD/hemp-infused cosmetic products, such as lotion and anti-aging cream.
While the sale of hemp and CBD oil in cosmetics is
permitted, China has not yet approved these products for use in food or
medicine; however, given worldwide legalization trends, this is likely to
change in the near future. CBD Biotech is an early player in China’s CBD
sector, and Wang is optimistic about the company’s future in the promising
market. “CBD-infused or hemp-infused cosmetic products [are] still very early
stage in China,” he said. “We are only one of few players in the market, and I
think 2020 will give us a lot of opportunities.”
The CIIX CEO views the growth of CBD Biotech as one of the
major milestones for CIIX in 2019. In mid-November of this year, CIIX’s
subsidiary was featured in a Wall Street Journal report about
the growing cannabis industry in China. CEO of CBD Biotech SEO Summer Yun
said (http://ibn.fm/1XUcw)
that “[a]s one of the first movers in the legal industrial hemp skincare and
cosmetics market, we are honored to be featured in this recent Wall
Street Journal report and believe that this mention validates our
efforts in China over the past few years.”
CIIX began in 1999. Two decades later, the company has a
promising subsidiary that is poised to become a major player in China’s
cannabis industry. While marijuana and THC are still illegal in China, Chinese
entrepreneurs are looking to cash in on China’s inevitable CBD boom.
When asked about his goals for 2020, CIIX’s ambitious CEO
had a lot to say. Wang noted that plans are in place to consolidate the China
and U.S. divisions, with headquarters in China. According to Wang, CBD Biotech
has already had more than 40,000 repeat purchase customers, and he believes
that the company will continue accumulating customers in 2020 through both B2B
and direct sales (http://ibn.fm/StJT1).
“China is a market that you cannot ignore in the next 10 to
20 years in the cannabis sectors,” said Wang, who expressed confidence that CBD
Biotech can accumulate millions of regular Chinese customers within the next
decade.
ChineseInvestors.com continues to help investors make
informed investment decisions and meet their individual financial goals. The
company is also at the vanguard of capitalizing on the convergence of CBD and
the nutrition- and health-products market in mainland China.
ChineseInvestors.com offers investors diverse revenue streams for potential
portfolio growth.
For more information, visit the company’s website at www.ChineseInvestors.com
NOTE TO INVESTORS: The latest news and updates
relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
